Other products in the same Health Canada class (N06BA) — coverage varies; not interchangeable
Dextroamphetamine (Dexedrine Spansules): general benefit
Lisdexamfetamine (Vyvanse): general benefit, Not a benefit
Mixed salt amphetamine (Adderall XR): general benefit
Modafinil (Alertec): not a benefit
Biphentin · DIN 02277166 · 10mg · extended release capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Biphentin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Biphentin · DIN 02277166
Manufacturer: Elvium Life Sciences; listing date 2009-08-18
Health Canada: Marketed since 2020-09-08 · brand BIPHENTIN · ATC N06BA04 METHYLPHENIDATE · form Capsule (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 10 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76281 · Verify on the e-Formulary ↗ (DIN 02277166)
Source record
DIN 02277166: Biphentin
Raw flags: sec3=Y
Item: 282000032; group id 516; item number 1384; lccId None; manufacturer id ELV
Source form: ER Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.0286; ministry $0.5128
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277166
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76281
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
PMS-Methylphenidate CR · DIN 02536943 · $0.5128
Shortage status: resolved shortage (ended 2023-07-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277166
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate CR: Formulary list price $0.5128/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5128 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102567 · Verify on the e-Formulary ↗ (DIN 02536943)
Source record
DIN 02536943: PMS-Methylphenidate CR
Raw flags: sec3=Y
Item: 282000032; group id 516; item number 1384; lccId None; manufacturer id PMS
Source form: ER Cap; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.5128; ministry $0.5128
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536943
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102567
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Biphentin · DIN 02277166 · $0.5128
Shortage status: resolved shortage (ended 2026-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536943
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Methylphenidate · DIN 02249324 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Methylphenidate · DIN 02249324
Manufacturer: Apotex Inc.; listing date 2005-03-31
Health Canada: Marketed since 2004-11-02 · brand APO-METHYLPHENIDATE · ATC N06BA04 METHYLPHENIDATE · form Tablet · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Controlled drugs (cdsa iii)
Apo-Methylphenidate: Formulary list price $0.2216/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2216 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73416 · Verify on the e-Formulary ↗ (DIN 02249324)
Source record
DIN 02249324: Apo-Methylphenidate
Raw flags: sec3=Y
Item: 282000004; group id 516; item number 1397; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.2216; ministry $0.2216
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02249324
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73416Interchangeable products
PMS-Methylphenidate · DIN 00584991 · $0.2216
Ritalin · DIN 00005606 · $0.2216
Shortage status: resolved shortage (ended 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02249324
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate · DIN 00584991 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Methylphenidate · DIN 00584991
Manufacturer: Pharmascience Inc.; listing date 1996-10-01
Health Canada: Marketed since 1998-12-15 · brand PMS-METHYLPHENIDATE · ATC N06BA04 METHYLPHENIDATE · form Tablet · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Controlled drugs (cdsa iii)
PMS-Methylphenidate: Formulary list price $0.2216/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2216 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10398 · Verify on the e-Formulary ↗ (DIN 00584991)
Source record
DIN 00584991: PMS-Methylphenidate
Raw flags: sec3=Y
Item: 282000004; group id 516; item number 1397; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.2216; ministry $0.2216
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00584991
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10398Interchangeable products
Apo-Methylphenidate · DIN 02249324 · $0.2216
Ritalin · DIN 00005606 · $0.2216
Shortage status: resolved shortage (ended 2025-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00584991
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biphentin · DIN 02277131 · 15mg · extended release capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Biphentin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Biphentin · DIN 02277131
Manufacturer: Elvium Life Sciences; listing date 2009-08-18
Health Canada: Marketed since 2020-09-03 · brand BIPHENTIN · ATC N06BA04 METHYLPHENIDATE · form Capsule (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 15 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76279 · Verify on the e-Formulary ↗ (DIN 02277131)
Source record
DIN 02277131: Biphentin
Raw flags: sec3=Y
Item: 282000033; group id 516; item number 1385; lccId None; manufacturer id ELV
Source form: ER Cap; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $1.4750; ministry $0.7354
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277131
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76279
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
PMS-Methylphenidate CR · DIN 02536951 · $0.7354
Shortage status: resolved shortage (ended 2022-09-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277131
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate CR: Formulary list price $0.7354/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.7354 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102568 · Verify on the e-Formulary ↗ (DIN 02536951)
Source record
DIN 02536951: PMS-Methylphenidate CR
Raw flags: sec3=Y
Item: 282000033; group id 516; item number 1385; lccId None; manufacturer id PMS
Source form: ER Cap; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $0.7354; ministry $0.7354
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536951
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102568
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Biphentin · DIN 02277131 · $0.7354
Shortage status: active shortage (reported 2026-05-22, estimated to end 2026-11-15, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536951
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Methylphenidate ER · DIN 02441934 · 18mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Methylphenidate ER · DIN 02441934
Manufacturer: Teva Canada Limited; listing date 2018-05-31
Health Canada: Marketed since 2020-03-03 · brand ACT METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 18 MG · company Teva canada limited · schedule Controlled drugs (cdsa iii)
Act Methylphenidate ER: Formulary list price $0.5246/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5246 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92630 · Verify on the e-Formulary ↗ (DIN 02441934)
Source record
DIN 02441934: Act Methylphenidate ER
Raw flags: sec3=Y
Item: 282000028; group id 516; item number 1393; lccId None; manufacturer id TEV
Source form: SR Tab; strength: 18mg
Recorded listing: General benefit
Source prices (unrounded): $0.5246; ministry $0.5246
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441934
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92630
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Apo-Methylphenidate ER · DIN 02452731 · $0.5246
Concerta · DIN 02247732 · $0.5246
Taro-Methylphenidate ER · DIN 02539004 · $0.5246
Shortage status: resolved shortage (ended 2024-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441934
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Methylphenidate ER · DIN 02452731 · 18mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Methylphenidate ER · DIN 02452731
Manufacturer: Apotex Inc.; listing date 2016-09-29
Health Canada: Marketed since 2016-07-22 · brand APO-METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 18 MG · company Apotex inc · schedule Controlled drugs (cdsa iii)
Apo-Methylphenidate ER: Formulary list price $0.5246/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5246 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93914 · Verify on the e-Formulary ↗ (DIN 02452731)
Source record
DIN 02452731: Apo-Methylphenidate ER
Raw flags: sec3=Y
Item: 282000028; group id 516; item number 1393; lccId None; manufacturer id APX
Source form: SR Tab; strength: 18mg
Recorded listing: General benefit
Source prices (unrounded): $0.5246; ministry $0.5246
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452731
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93914
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441934 · $0.5246
Concerta · DIN 02247732 · $0.5246
Taro-Methylphenidate ER · DIN 02539004 · $0.5246
Shortage status: resolved shortage (ended 2025-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02452731
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Concerta · DIN 02247732 · 18mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Concerta (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Concerta (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Concerta · DIN 02247732
Manufacturer: Janssen Inc.; listing date 2009-04-01
Health Canada: Marketed since 2003-07-23 · brand CONCERTA · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 18 MG · company Janssen inc · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72012 · Verify on the e-Formulary ↗ (DIN 02247732)
Source record
DIN 02247732: Concerta
Raw flags: sec3=Y
Item: 282000028; group id 516; item number 1393; lccId None; manufacturer id JAN
Source form: SR Tab; strength: 18mg
Recorded listing: General benefit
Source prices (unrounded): $3.2995; ministry $0.5246
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247732
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72012
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441934 · $0.5246
Apo-Methylphenidate ER · DIN 02452731 · $0.5246
Taro-Methylphenidate ER · DIN 02539004 · $0.5246
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247732
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Methylphenidate ER · DIN 02539004 · 18mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Methylphenidate ER · DIN 02539004
Manufacturer: Sun Pharma; listing date 2026-08-31
Health Canada: Marketed since 2026-05-01 · brand TARO-METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 18 MG · company Sun pharma canada inc · schedule Controlled drugs (cdsa iii)
Taro-Methylphenidate ER: Formulary list price $0.5246/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5246 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102767 · Verify on the e-Formulary ↗ (DIN 02539004)
Source record
DIN 02539004: Taro-Methylphenidate ER
Raw flags: sec3=Y
Item: 282000028; group id 516; item number 1393; lccId None; manufacturer id SPC
Source form: SR Tab; strength: 18mg
Recorded listing: General benefit
Source prices (unrounded): $0.5246; ministry $0.5246
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539004
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102767
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441934 · $0.5246
Apo-Methylphenidate ER · DIN 02452731 · $0.5246
Concerta · DIN 02247732 · $0.5246
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539004
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biphentin · DIN 02277158 · 20mg · extended release capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Biphentin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Biphentin · DIN 02277158
Manufacturer: Elvium Life Sciences; listing date 2009-08-18
Health Canada: Marketed since 2020-09-03 · brand BIPHENTIN · ATC N06BA04 METHYLPHENIDATE · form Capsule (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 20 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76280 · Verify on the e-Formulary ↗ (DIN 02277158)
Source record
DIN 02277158: Biphentin
Raw flags: sec3=Y
Item: 282000034; group id 516; item number 1386; lccId None; manufacturer id ELV
Source form: ER Cap; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $1.9006; ministry $0.9477
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277158
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76280
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects,administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
PMS-Methylphenidate CR · DIN 02536978 · $0.9477
Shortage status: resolved shortage (ended 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate CR: Formulary list price $0.9477/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9477 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102569 · Verify on the e-Formulary ↗ (DIN 02536978)
Source record
DIN 02536978: PMS-Methylphenidate CR
Raw flags: sec3=Y
Item: 282000034; group id 516; item number 1386; lccId None; manufacturer id PMS
Source form: ER Cap; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.9477; ministry $0.9477
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536978
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102569
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects,administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Biphentin · DIN 02277158 · $0.9477
Shortage status: resolved shortage (ended 2026-06-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536978
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AA-Methylphenidate SR · DIN 02266687 · 20mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Methylphenidate SR · DIN 02266687
Manufacturer: A A Pharma Inc.; listing date 2006-07-19
Health Canada: Marketed since 2026-03-23 · brand AA-METHYLPHENIDATE SR · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 20 MG · company Aa pharma inc · schedule Controlled drugs (cdsa iii)
AA-Methylphenidate SR: Formulary list price $0.6796/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6796 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75209 · Verify on the e-Formulary ↗ (DIN 02266687)
Source record
DIN 02266687: AA-Methylphenidate SR
Raw flags: sec3=Y
Item: 282000006; group id 516; item number 1392; lccId None; manufacturer id AAP
Source form: ER Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.6796; ministry $0.6796
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266687
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75209Interchangeable products
Ritalin SR · DIN 00632775 · not recorded
Shortage status: resolved shortage (ended 2021-02-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266687
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Foquest · DIN 02470292 · 25mg · CR capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Foquest · DIN 02470292
Manufacturer: Elvium Life Sciences; listing date 2023-04-28
Health Canada: Marketed since 2020-09-08 · brand FOQUEST · ATC N06BA04 METHYLPHENIDATE · form Capsule (controlled-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 25 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Foquest: Formulary list price $3.0357/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.0357 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95927 · Verify on the e-Formulary ↗ (DIN 02470292)
Source record
DIN 02470292: Foquest
Raw flags: sec3=Y
Item: 282000080; group id 516; item number 1377; lccId None; manufacturer id ELV
Source form: CR Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $3.0357; ministry $3.0357
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470292
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95927
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Shortage status: resolved shortage (ended 2023-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470292
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Methylphenidate ER · DIN 02441942 · 27mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Methylphenidate ER · DIN 02441942
Manufacturer: Teva Canada Limited; listing date 2018-05-31
Health Canada: Marketed since 2020-03-03 · brand ACT METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 27 MG · company Teva canada limited · schedule Controlled drugs (cdsa iii)
Act Methylphenidate ER: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6055 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92631 · Verify on the e-Formulary ↗ (DIN 02441942)
Source record
DIN 02441942: Act Methylphenidate ER
Raw flags: sec3=Y
Item: 282000031; group id 516; item number 1394; lccId None; manufacturer id TEV
Source form: SR Tab; strength: 27mg
Recorded listing: General benefit
Source prices (unrounded): $0.6055; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441942
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92631
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Apo-Methylphenidate ER · DIN 02452758 · $0.6055
Concerta · DIN 02250241 · $0.6055
Taro-Methylphenidate ER · DIN 02539012 · $0.6055
Shortage status: resolved shortage (ended 2024-02-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441942
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Methylphenidate ER · DIN 02452758 · 27mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Methylphenidate ER · DIN 02452758
Manufacturer: Apotex Inc.; listing date 2016-09-29
Health Canada: Marketed since 2016-07-22 · brand APO-METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 27 MG · company Apotex inc · schedule Controlled drugs (cdsa iii)
Apo-Methylphenidate ER: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6055 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93915 · Verify on the e-Formulary ↗ (DIN 02452758)
Source record
DIN 02452758: Apo-Methylphenidate ER
Raw flags: sec3=Y
Item: 282000031; group id 516; item number 1394; lccId None; manufacturer id APX
Source form: SR Tab; strength: 27mg
Recorded listing: General benefit
Source prices (unrounded): $0.6055; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452758
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93915
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441942 · $0.6055
Concerta · DIN 02250241 · $0.6055
Taro-Methylphenidate ER · DIN 02539012 · $0.6055
Shortage status: resolved shortage (ended 2025-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02452758
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Concerta · DIN 02250241 · 27mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Concerta (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Concerta (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Concerta · DIN 02250241
Manufacturer: Janssen Inc.; listing date 2009-04-01
Health Canada: Marketed since 2005-01-06 · brand CONCERTA · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 27 MG · company Janssen inc · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73505 · Verify on the e-Formulary ↗ (DIN 02250241)
Source record
DIN 02250241: Concerta
Raw flags: sec3=Y
Item: 282000031; group id 516; item number 1394; lccId None; manufacturer id JAN
Source form: SR Tab; strength: 27mg
Recorded listing: General benefit
Source prices (unrounded): $3.8076; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250241
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73505
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441942 · $0.6055
Apo-Methylphenidate ER · DIN 02452758 · $0.6055
Taro-Methylphenidate ER · DIN 02539012 · $0.6055
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02250241
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Methylphenidate ER · DIN 02539012 · 27mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Methylphenidate ER · DIN 02539012
Manufacturer: Sun Pharma; listing date 2026-08-31
Health Canada: Marketed since 2026-05-01 · brand TARO-METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 27 MG · company Sun pharma canada inc · schedule Controlled drugs (cdsa iii)
Taro-Methylphenidate ER: Formulary list price $0.6055/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6055 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102768 · Verify on the e-Formulary ↗ (DIN 02539012)
Source record
DIN 02539012: Taro-Methylphenidate ER
Raw flags: sec3=Y
Item: 282000031; group id 516; item number 1394; lccId None; manufacturer id SPC
Source form: SR Tab; strength: 27mg
Recorded listing: General benefit
Source prices (unrounded): $0.6055; ministry $0.6055
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539012
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102768
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Act Methylphenidate ER · DIN 02441942 · $0.6055
Apo-Methylphenidate ER · DIN 02452758 · $0.6055
Concerta · DIN 02250241 · $0.6055
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02539012
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biphentin · DIN 02277174 · 30mg · extended release capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Biphentin (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Biphentin · DIN 02277174
Manufacturer: Elvium Life Sciences; listing date 2009-08-18
Health Canada: Marketed since 2020-09-08 · brand BIPHENTIN · ATC N06BA04 METHYLPHENIDATE · form Capsule (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 30 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76282 · Verify on the e-Formulary ↗ (DIN 02277174)
Source record
DIN 02277174: Biphentin
Raw flags: sec3=Y
Item: 282000035; group id 516; item number 1387; lccId None; manufacturer id ELV
Source form: ER Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $2.6118; ministry $1.3021
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277174
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76282
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
PMS-Methylphenidate CR · DIN 02536986 · $1.3021
Shortage status: resolved shortage (ended 2023-07-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277174
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate CR: Formulary list price $1.3021/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3021 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102570 · Verify on the e-Formulary ↗ (DIN 02536986)
Source record
DIN 02536986: PMS-Methylphenidate CR
Raw flags: sec3=Y
Item: 282000035; group id 516; item number 1387; lccId None; manufacturer id PMS
Source form: ER Cap; strength: 30mg
Recorded listing: General benefit
Source prices (unrounded): $1.3021; ministry $1.3021
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536986
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102570
Therapeutic Notes (formulary)
Note: Patients > 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Biphentin · DIN 02277174 · $1.3021
Shortage status: resolved shortage (ended 2026-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536986
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Foquest · DIN 02470306 · 35mg · CR capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Foquest · DIN 02470306
Manufacturer: Elvium Life Sciences; listing date 2023-04-28
Health Canada: Marketed since 2020-09-08 · brand FOQUEST · ATC N06BA04 METHYLPHENIDATE · form Capsule (controlled-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 35 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Foquest: Formulary list price $3.3388/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.3388 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95928 · Verify on the e-Formulary ↗ (DIN 02470306)
Source record
DIN 02470306: Foquest
Raw flags: sec3=Y
Item: 282000081; group id 516; item number 1378; lccId None; manufacturer id ELV
Source form: CR Cap; strength: 35mg
Recorded listing: General benefit
Source prices (unrounded): $3.3388; ministry $3.3388
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470306
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95928
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Shortage status: resolved shortage (ended 2023-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470306
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Methylphenidate ER · DIN 02441950 · 36mg · extended release tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Methylphenidate ER · DIN 02441950
Manufacturer: Teva Canada Limited; listing date 2018-05-31
Health Canada: Marketed since 2020-03-03 · brand ACT METHYLPHENIDATE ER · ATC N06BA04 METHYLPHENIDATE · form Tablet (extended-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 36 MG · company Teva canada limited · schedule Controlled drugs (cdsa iii)
Act Methylphenidate ER: Formulary list price $0.6863/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6863 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92632 · Verify on the e-Formulary ↗ (DIN 02441950)
Source record
DIN 02441950: Act Methylphenidate ER
Raw flags: sec3=Y
Item: 282000029; group id 516; item number 1395; lccId None; manufacturer id TEV
Source form: SR Tab; strength: 36mg
Recorded listing: General benefit
Source prices (unrounded): $0.6863; ministry $0.6863
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441950
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92632
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.Interchangeable products
Apo-Methylphenidate ER · DIN 02452766 · $0.6863
Concerta · DIN 02247733 · $0.6863
Taro-Methylphenidate ER · DIN 02539020 · $0.6863
Shortage status: resolved shortage (ended 2024-02-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441950
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Methylphenidate · DIN 02249332 · 20mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Methylphenidate · DIN 02249332
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Marketed since 2004-11-02 · brand APO-METHYLPHENIDATE · ATC N06BA04 METHYLPHENIDATE · form Tablet · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 20 MG · company Apotex inc · schedule Controlled drugs (cdsa iii)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73417 · Verify on the e-Formulary ↗ (DIN 02249332)
Source record
DIN 02249332: Apo-Methylphenidate
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282000039; group id 516; item number 1398; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3536; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02249332
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73417Interchangeable products
PMS-Methylphenidate · DIN 00585009 · not recorded
Ritalin · DIN 00005614 · not recorded
Shortage status: resolved shortage (ended 2021-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02249332
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Methylphenidate · DIN 00585009 · 20mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Methylphenidate · DIN 00585009
Manufacturer: Pharmascience Inc.; listing date 2008-01-15
Health Canada: Marketed since 1998-12-15 · brand PMS-METHYLPHENIDATE · ATC N06BA04 METHYLPHENIDATE · form Tablet · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 20 MG · company Pharmascience inc · schedule Controlled drugs (cdsa iii)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10399 · Verify on the e-Formulary ↗ (DIN 00585009)
Source record
DIN 00585009: PMS-Methylphenidate
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282000039; group id 516; item number 1398; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3536; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00585009
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10399Interchangeable products
Apo-Methylphenidate · DIN 02249332 · not recorded
Ritalin · DIN 00005614 · not recorded
Shortage status: resolved shortage (ended 2018-08-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00585009
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:20 C.N.S. Stimulants) and how they are covered
Matched class: 28:20 C.N.S. Stimulants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DEXTROAMPHETAMINE SULFATE, MIXED SALT AMPHETAMINE
Some products covered without a code (check the product listing): LISDEXAMFETAMINE DIMESYLATE
28:20 C.N.S. Stimulants
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: DEXTROAMPHETAMINE SULFATE, MIXED SALT AMPHETAMINE
ATOMOXETINE HCL · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14)
Need for Comprehensive Treatment Program
TEVA-ATOMOXETINE is indicated as an integral part of a total treatment program for ADHD
that may include other measures (psychological, educational, and social) for patients with this
syndrome.
PM: https://pdf.hres.ca/dpd_pm/00052053.PDF; date July 2, 2019; DIN 02314541; fetched 2026-09-10
Product monographDEXTROAMPHETAMINE SULFATE · General benefit
Need for Comprehensive Treatment Program: DEXEDRINE/DEXEDRINE SPANSULE is indicated
as an integral part of a total treatment program for ADHD that may include other measures
(psychological, educational and social) for patients with this syndrome.
PM: https://pdf.hres.ca/dpd_pm/00083629.PDF; date FEB 25, 2026; DIN 01924516; fetched 2026-09-10
Product monographGUANFACINE · Limited Use, codes 540
Need for Comprehensive Treatment Program
INTUNIV XR is indicated as an integral part of a total treatment program for ADHD that may include
other measures (psychological, educational/vocational, social) for patients with this syndrome.
PM: https://pdf.hres.ca/dpd_pm/00082036.PDF; date not captured; DIN 02409100; fetched 2026-09-10
Product monographLISDEXAMFETAMINE DIMESYLATE · General benefit (54), Off-Formulary Interchangeable, not an ODB benefit (6)
Need for Comprehensive Treatment Program
VYVANSE is indicated as an integral part of a total treatment program for ADHD that may
include other measures (psychological, educational/vocational, social) for patients with this
syndrome.
PM: https://pdf.hres.ca/dpd_pm/00081828.PDF; date 2025-09-15; DIN 02322951; fetched 2026-09-10
Product monographMIXED SALT AMPHETAMINE · General benefit
Indications
ADDERALL XR (mixed salts amphetamine extended-release capsules) is indicated for the treatment of
Attention Deficit Hyperactivity Disorder (ADHD) in:
• Children (6 – 12 years of age)
• Adolescents (13 – 17 years of age)
• Adults (18 years of age or older)
Need for Comprehensive Treatment Program
ADDERALL XR is indicated as an integral part of a total treatment program for ADHD that may include
other measures (psychological, educational, social) for patients with this syndrome.
PM: https://pdf.hres.ca/dpd_pm/00081719.PDF; date 2025-09-12; DIN 02248808; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATION AND CLINICAL USE
pms-METHYLPHENIDATE is indicated for the treatment of:
Attention Deficit Hyperactivity Disorder (ADHD)
Need for Comprehensive Treatment Program
pms-METHYLPHENIDATE is indicated as an integral part of a total treatment program for
ADHD that may include other measures (psychological, educational, social) for patients with this
syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug
treatment is not intended for use in the patient who exhibits symptoms secondary to
environmental factors and/or other primary psychiatric disorders, including psychosis.
Appropriate educational placement is essential in children and adolescents with this diagnosis
and psychosocial intervention is often helpful. When remedial measures alone are insufficient,
the decision to prescribe drug treatment medication will depend upon the healthcare
professional’s assessment of the chronicity and severity of the patient’s symptoms.
Long-Term Use
The effectiveness of Methylphenidate Hydrochloride Tablets for long-term use, i.e. for more
than 4 weeks has not been systematically evaluated in placebo-controlled trials. Therefore, the
healthcare profe…
https://pdf.hres.ca/dpd_pm/00068339.PDF
PM date: October 17, 2022
Source product: PMS-METHYLPHENIDATE; DIN 00584991; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PMS-Methylphenidate CR · DIN 02536951
Shortage status: active shortage (reported 2026-05-22, estimated to end 2026-11-15, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02536951
For Apo-Methylphenidate, PMS-Methylphenidate: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.